You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 111 No. 12, December 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Iridium-192 Implants in the Treatment of Tonsillar Region Malignancies

Ajmel A. Puthawala, MD; A. M. Nisar Syed, MD; Thomas C. Gates, MD

Arch Otolaryngol. 1985;111(12):812-815.


Abstract

• A total of 127 patients with histologically proved diagnosis of carcinoma of the tonsillar region and soft palate were treated over the past ten years utilizing interstitial iridium-192 implants. Eighty patients were treated for primary tumors and 47 patients for either recurrent or persistent tumors after definitive irradiation and/or surgery. All patients with primary tumors were treated by a combination of external megavoltage irradiation and interstitial iridium-192 implants, whereas patients with recurrent tumors were treated by interstitial implants alone. In the primary group, 95% of patients with T1 and T2 lesions and 79% with T3 and T4 lesions achieved complete local tumor control. The three-year absolute disease-free survival rate was 72%. Seventy-five percent local tumor control was obtained in patients with recurrent disease, with two-year absolute disease-free survival of 42%. Treatment-related complications such as soft-tissue necrosis or osteoradionecrosis occurred in 6% of patients in the primary group and 23% in recurrent group. This treatment regimen offers an excellent locoregional control with no significant functional or esthetic impairment. Most patients with primary lesions who fail this regimen can be salvaged by surgery or reirradiation using interstitial implants. Reirradiation with interstitial implants is feasible and offers a good chance of long-term local tumor control in the selected group of patients with recurrent disease for whom external irradiation and/or surgery had not been successful.

(Arch Otolaryngol 1985;111:812-815)



Author Affiliations

From the University of California, Irvine (Drs Puthawala and Syed), the Memorial Medical Center (Drs Puthawala and Syed), and St Mary's Medical Center (Dr Gates), Long Beach, Calif.


Footnotes

Accepted for publication April 16, 1985.

Read before the international conference on Head and Neck Cancer, Baltimore, July 23, 1984.

Reprint requests to 1245 Wilshire Blvd, Suite 217, Los Angeles, CA 90017 (Dr Puthawala).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Chemo-reirradiation in Persistent/Recurrent Head and Neck Cancers
Nagar et al.
Jpn J Clin Oncol 2004;34:61-68.
ABSTRACT | FULL TEXT  

Simultaneous Interstitial Radiotherapy With Regional or Free-Flap Reconstruction, Following Salvage Surgery of Recurrent Head and Neck Carcinoma: Analysis of Complications
Moscoso et al.
Arch Otolaryngol Head Neck Surg 1994;120:965-972.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.